Third, formal budget-impact and cost-effectiveness models should quantify the medium-term fiscal implications of expanding GLP-1-based and SGLT-2 indications, including obesity and MASLD, under alternative reimbursement and pricing scenarios. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.